IMMUNEONCO-B (01541) Company Profile - Company Info, Industry & Management

返回 Overview News Financials Shareholders Valuation Profile IPO ›

Industry

Innovative Drugs & Biologics 0.02%

124 stocks in this industry

3 >7%

3 5~7%

10 3~5%

36 0~3%

15 0%

38 0~3%

13 3~5%

1 5~7%

5 >7%

Down 52 Up 57

Industry RankingsValue (HKD)Rank

Revenue (Last FY)180.94M81/112

Net Profit (Last FY)-256.32M87/125

ROE (Last FY)-27.62%87/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition

Tian Wenzhi Executive Director

Li Song Executive Director

Guan Mei Executive Director

Zhang Ruliang Executive Director

Xu Cong Non-Executive Director

Fu Dawei Non-Executive Director

Zhenping Zhu Independent Non-Executive Director

Kendall Arthur Smith Independent Non-Executive Director

Yeung Chi Tat Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2025-06-30.

About this page

This page shows IMMUNEONCO-B (01541) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

IMMUNEONCO-B 01541

Company Information

Industry

Management

IMMUNEONCO-B 01541·

Company Information

Industry

Management

IMMUNEONCO-B 01541